Munich, Germany

Henner Graeff


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Henner Graeff: Innovator in Diagnostic and Therapeutic Applications

Introduction

Henner Graeff is a notable inventor based in Munich, Germany. He has made significant contributions to the field of diagnostics and therapeutics, particularly through his innovative work involving antibodies against the urokinase receptor. His research has the potential to impact cancer detection and treatment.

Latest Patents

Henner Graeff holds 1 patent for his invention titled "Diagnostic and therapeutic use of antibodies against the urokinase receptor." This patent describes a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique. The invention focuses on the diagnostic and therapeutic application of amino acid sequence-specific antibodies against the urokinase receptor, which exhibit a high affinity for tumor cell-expressed receptors.

Career Highlights

Henner Graeff is associated with Wilex AG, a company that specializes in the development of innovative cancer therapies. His work at Wilex AG has allowed him to explore the therapeutic potential of his inventions in a practical setting. His dedication to advancing medical technology is evident in his research and development efforts.

Collaborations

Henner Graeff has collaborated with notable colleagues, including Manfred Schmitt and Frank Noack. These collaborations have likely contributed to the success of his research and the development of his patented technologies.

Conclusion

Henner Graeff's contributions to the field of diagnostics and therapeutics highlight the importance of innovation in medical science. His work with antibodies against the urokinase receptor represents a significant advancement in cancer detection and treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…